{
    "xml": "<topic id=\"PHP8617\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/cisatracurium\" basename=\"cisatracurium\" title=\"CISATRACURIUM\">\n<title>CISATRACURIUM</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_622\" namespace=\"/interactions/list-of-drug-interactions/muscle-relaxants/muscle-relaxants-non-depolarising/cisatracurium\">Cisatracurium</xref>\n</p>\n<data name=\"vtmid\">108452005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_514498464\" title=\"Neuromuscular blocking drugs (non-depolarising)\">Neuromuscular blocking drugs (non-depolarising)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34607\" title=\"NON-DEPOLARISING NEUROMUSCULAR BLOCKING DRUGS\" namespace=\"/drug-classes/non-depolarising-neuromuscular-blocking-drugs\">NON-DEPOLARISING NEUROMUSCULAR BLOCKING DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP57759\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/cisatracurium\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Neuromuscular blockade (intermediate duration) during surgery and intubation</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 150&#8239;micrograms/kg, then (by intravenous injection) maintenance 30&#8239;micrograms/kg every 20&#8239;minutes, alternatively (by intravenous infusion) initially 180&#8239;micrograms/kg/hour, then (by intravenous infusion) maintenance 60&#8211;120&#8239;micrograms/kg/hour, maintenance dose administered after stabilisation.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Neuromuscular blockade (intermediate duration) during intensive care</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 150&#8239;micrograms/kg, initial dose is optional, then (by intravenous infusion) 180&#8239;micrograms/kg/hour, adjusted according to response; (by intravenous infusion) usual dose 30&#8211;600&#8239;micrograms/kg/hour.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"extremesOfBodyWeight\">\n<title>Doses at extremes of body-weight</title>\n<p>To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57709\" outputclass=\"sideEffects\" rev=\"1.13\" parent=\"/drugs/cisatracurium\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Acute myopathy (after prolonged use in intensive care)</ph>; <ph outputclass=\"sideEffect\">bradycardia</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57876\" outputclass=\"directionsForAdministration\" rev=\"1.10\" parent=\"/drugs/cisatracurium\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Nimbex</i>\n<tm tmtype=\"reg\"/>, <i>Nimbex Forte</i>\n<tm tmtype=\"reg\"/>), give continuously in Glucose 5% or Sodium Chloride 0.9%; solutions of 2&#8239;mg/mL and 5&#8239;mg/mL may be infused undiluted; alternatively dilute with infusion fluid to a concentration of 0.1&#8211;2&#8239;mg/mL.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP8617-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/cisatracurium\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75874\" title=\"Solution for injection\" namespace=\"/drugs/cisatracurium/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78426\" namespace=\"/treatment-summaries/neuromuscular-blockade\" title=\"Neuromuscular blockade\" count=\"3\" rel=\"backlink\">Neuromuscular blockade</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_622\" namespace=\"/interactions/list-of-drug-interactions/muscle-relaxants/muscle-relaxants-non-depolarising/cisatracurium\" title=\"Cisatracurium\" count=\"1\" rel=\"link\">Cisatracurium</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34607\" namespace=\"/drug-classes/non-depolarising-neuromuscular-blocking-drugs\" title=\"NON-DEPOLARISING NEUROMUSCULAR BLOCKING DRUGS\" count=\"1\" rel=\"link\">NON-DEPOLARISING NEUROMUSCULAR BLOCKING DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75874\" namespace=\"/drugs/cisatracurium/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP8617",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/cisatracurium",
    "basename": "cisatracurium",
    "title": "CISATRACURIUM",
    "interactants": [
        {
            "id": "bnf_int_622",
            "label": "Cisatracurium"
        }
    ],
    "vtmid": "108452005",
    "drugClassification": [
        "Neuromuscular blocking drugs (non-depolarising)"
    ],
    "inheritsFromClass": [
        "NON-DEPOLARISING NEUROMUSCULAR BLOCKING DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Neuromuscular blockade (intermediate duration) during surgery and intubation",
                        "html": "Neuromuscular blockade (intermediate duration) during surgery and intubation"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection"
                    ],
                    "textContent": "Initially by intravenous injection",
                    "html": "Initially by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 150 micrograms/kg, then (by intravenous injection) maintenance 30 micrograms/kg every 20 minutes, alternatively (by intravenous infusion) initially 180 micrograms/kg/hour, then (by intravenous infusion) maintenance 60&#8211;120 micrograms/kg/hour, maintenance dose administered after stabilisation.",
                        "html": "<p>Initially 150&#8239;micrograms/kg, then (by intravenous injection) maintenance 30&#8239;micrograms/kg every 20&#8239;minutes, alternatively (by intravenous infusion) initially 180&#8239;micrograms/kg/hour, then (by intravenous infusion) maintenance 60&#8211;120&#8239;micrograms/kg/hour, maintenance dose administered after stabilisation.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Neuromuscular blockade (intermediate duration) during intensive care",
                        "html": "Neuromuscular blockade (intermediate duration) during intensive care"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection"
                    ],
                    "textContent": "Initially by intravenous injection",
                    "html": "Initially by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 150 micrograms/kg, initial dose is optional, then (by intravenous infusion) 180 micrograms/kg/hour, adjusted according to response; (by intravenous infusion) usual dose 30&#8211;600 micrograms/kg/hour.",
                        "html": "<p>Initially 150&#8239;micrograms/kg, initial dose is optional, then (by intravenous infusion) 180&#8239;micrograms/kg/hour, adjusted according to response; (by intravenous infusion) usual dose 30&#8211;600&#8239;micrograms/kg/hour.</p>"
                    }
                ]
            }
        ],
        "extremesOfBodyWeight": [
            {
                "type": "extremesOfBodyWeight",
                "title": "Doses at extremes of body-weight",
                "textContent": "To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.",
                "html": "<p>To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Acute myopathy (after prolonged use in intensive care)",
                        "html": "Acute myopathy (after prolonged use in intensive care)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bradycardia",
                        "html": "bradycardia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Nimbex , Nimbex Forte ), give continuously in Glucose 5% or Sodium Chloride 0.9%; solutions of 2 mg/mL and 5 mg/mL may be infused undiluted; alternatively dilute with infusion fluid to a concentration of 0.1&#8211;2 mg/mL.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Nimbex</i>\n<tm tmtype=\"reg\"/>, <i>Nimbex Forte</i>\n<tm tmtype=\"reg\"/>), give continuously in Glucose 5% or Sodium Chloride 0.9%; solutions of 2&#8239;mg/mL and 5&#8239;mg/mL may be infused undiluted; alternatively dilute with infusion fluid to a concentration of 0.1&#8211;2&#8239;mg/mL.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75874",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78426",
                "label": "Neuromuscular blockade",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_622",
                "label": "Cisatracurium",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34607",
                "label": "NON-DEPOLARISING NEUROMUSCULAR BLOCKING DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75874",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}